

# Angelo Paci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4717072/publications.pdf>

Version: 2024-02-01

142  
papers

4,436  
citations

126858

33  
h-index

128225

60  
g-index

155  
all docs

155  
docs citations

155  
times ranked

7374  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. Journal of Hematology and Oncology, 2022, 15, 6.	6.9	17
2	Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Leukemia and Lymphoma, 2021, 62, 438-445.	0.6	5
3	The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma. Oncologist, 2021, 26, 389-396.	1.9	8
4	Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population. Pharmaceuticals, 2021, 14, 272.	1.7	7
5	Multicentric phase II trial of Tlâ€CE highâ€dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. Cancer Medicine, 2021, 10, 2250-2258.	1.3	3
6	Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC. Pharmaceuticals, 2021, 14, 927.	1.7	3
7	Late phase 1 studies: concepts and outcomes. Lancet Oncology, The, 2021, 22, e446-e455.	5.1	2
8	Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open, 2021, 6, 100312.	2.0	17
9	Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?. Clinical Cancer Research, 2020, 26, 787-792.	3.2	44
10	Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma. Neuro-Oncology Advances, 2020, 2, vdaa075.	0.4	2
11	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 421-428.	0.4	3
12	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biology of Blood and Marrow Transplantation, 2020, 26, e235-e236.	2.0	0
13	New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning. Pediatric Blood and Cancer, 2020, 67, e28603.	0.8	7
14	Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects. , 2020, 8, e000916.		1
15	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers, 2020, 12, 3758.	1.7	4
16	1166MO Clinical evaluation of serum succinate levels as a new biomarker in SDH-related paragangliomas and pheochromocytomas. Annals of Oncology, 2020, 31, S773-S774.	0.6	2
17	727P Cabozantinib (Cabo) concentration (Cmin) association with toxicity (tox) and treatment failure in metastatic renal cell carcinoma (mRCC) patients: The MONICA study. Annals of Oncology, 2020, 31, S569-S570.	0.6	0
18	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. Journal of Clinical Oncology, 2020, 38, 2762-2772.	0.8	80

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. <i>European Journal of Cancer</i> , 2020, 128, 119-128.	1.3	50
20	Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?. <i>European Journal of Cancer</i> , 2020, 128, 103-106.	1.3	7
21	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers. <i>European Journal of Cancer</i> , 2020, 128, 107-118.	1.3	36
22	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. <i>Nature Communications</i> , 2020, 11, 2168.	5.8	231
23	Prodrugs as drug delivery system in oncology. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 937-958.	1.1	23
24	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1890-1897.	2.0	19
25	Biodegradable Pickering emulsions of Lipiodol for liver trans-arterial chemo-embolization. <i>Acta Biomaterialia</i> , 2019, 87, 177-186.	4.1	30
26	Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 112-124.	2.0	11
27	Potential of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. <i>International Journal of Oncology</i> , 2019, 54, 2149-2156.	1.4	8
28	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 1486.	5.8	189
29	Intestinal bacterial $\beta$ -glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. , 2019, 199, 1-15.		59
30	MA21.09 Tyrosine Kinase Inhibitors' Plasma Concentration and Oncogene-Addicted Advanced Non-Small Lung Cancer (aNSCLC) Resistance. <i>Journal of Thoracic Oncology</i> , 2019, 14, S337-S338.	0.5	2
31	1,1-Diheterocyclic Ethylenes Derived from Quinaldine and Carbazole as New Tubulin-Polymerization Inhibitors: Synthesis, Metabolism, and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1902-1916.	2.9	43
32	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. <i>Leukemia</i> , 2018, 32, 2008-2081.	3.3	18
33	Pickering-Emulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 781-788.	0.9	28
34	Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. <i>European Journal of Cancer</i> , 2018, 91, 56-67.	1.3	8
35	Curcumin dietary supplements and everolimus-based cancer treatment. <i>Annals of Oncology</i> , 2018, 29, 287-288.	0.6	7
36	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase "mutated intrahepatic cholangiocarcinomas. <i>European Journal of Cancer</i> , 2018, 90, 83-91.	1.3	28

#	ARTICLE	IF	CITATIONS
37	What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?. <i>Bioanalysis</i> , 2018, 10, 723-735.	0.6	12
38	Serum 2-Hydroxyglutarate in Angioimmunoblastic T Cell Lymphomas: A New Marker for IDH2 Mutation Detection and Monitoring. <i>Blood</i> , 2018, 132, 2898-2898.	0.6	1
39	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 478-493.	7.7	350
40	Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient. <i>Annales D'Endocrinologie</i> , 2017, 78, 67-69.	0.6	4
41	Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2017, 81, 81-89.	1.3	11
42	Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies. <i>International Journal of Pharmaceutics</i> , 2017, 532, 748-756.	2.6	1
43	Busulfan after HSCT in children and young adults. <i>Lancet Haematology</i> , 2017, 4, e103.	2.2	2
44	Stabilization Improves Theranostic Properties of Lipiodol®-Based Emulsion During Liver Trans-arterial Chemo-embolization in a VX2 Rabbit Model. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 907-913.	0.9	12
45	Colchicine is an active treatment for everolimus-induced oral ulcers. <i>European Journal of Cancer</i> , 2017, 87, 209-211.	1.3	4
46	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. <i>Clinical Cancer Research</i> , 2017, 23, 7171-7179.	3.2	15
47	Ultrasound-induced mild hyperthermia improves the anticancer efficacy of both Taxol® and paclitaxel-loaded nanocapsules. <i>Journal of Controlled Release</i> , 2017, 264, 219-227.	4.8	36
48	Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. <i>European Journal of Cancer</i> , 2017, 83, 194-202.	1.3	14
49	Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. <i>Seminars in Oncology</i> , 2017, 44, 159-160.	0.8	5
50	Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC. <i>International Journal of Pharmaceutics</i> , 2017, 531, 143-152.	2.6	19
51	Parameters for Stable Water-in-Oil Lipiodol Emulsion for Liver Trans-Arterial Chemo-Eembolization. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1927-1932.	0.9	30
52	Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. <i>Investigational New Drugs</i> , 2017, 35, 247-249.	1.2	8
53	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. <i>Cancer Research</i> , 2017, 77, 557-565.	0.4	10
54	Individualized Pazopanib Dosing Letter. <i>Clinical Cancer Research</i> , 2016, 22, 6298-6298.	3.2	4

#	ARTICLE	IF	CITATIONS
55	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 15084-15089.	3.3	96
56	Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1022, 290-297.	1.2	30
57	Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration. <i>Bone Marrow Transplantation</i> , 2016, 51, 1265-1267.	1.3	6
58	Familial hematological malignancies: new IDH2 mutation. <i>Annals of Hematology</i> , 2016, 95, 1943-1947.	0.8	7
59	Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2016, 115, 549-552.	2.9	11
60	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1915-1925.	2.0	130
61	Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice. <i>Pharmaceutical Research</i> , 2016, 33, 1913-1922.	1.7	15
62	Antineoplastic busulfan encapsulated in a metal organic framework nanocarrier: first in vivo results. <i>Journal of Materials Chemistry B</i> , 2016, 4, 585-588.	2.9	34
63	Dyslipidemia causes overestimation of plasma mitotane measurements. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 150135.	0.2	3
64	Nilotinib versus imatinib for GIST. <i>Lancet Oncology</i> , The, 2015, 16, e311.	5.1	2
65	Safety and Efficacy Compared between Irinotecan-Loaded Microspheres HepaSphere and DC Bead in a Model of VX2 Liver Metastases in the Rabbit. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1067-1075.e3.	0.2	17
66	Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2890-2898.	1.8	30
67	Simultaneous quantification of preactivated ifosfamide derivatives and of 4-hydroxyifosfamide by high performance liquid chromatography-tandem mass spectrometry in mouse plasma and its application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 992, 30-35.	1.2	3
68	Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. <i>Annals of Oncology</i> , 2015, 26, 1500-1504.	0.6	24
69	A case of melphalan sustained accumulation in an 80-year old patient. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 984-987.	1.0	4
70	Stability of Melphalan in 0.9% Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection. <i>Drugs in R and D</i> , 2015, 15, 253-259.	1.1	10
71	Preactivated Oxazaphosphorines Designed for Isophosphoramidate Mustard Delivery as Bulk Form or Nanoassemblies: Synthesis and Proof of Concept. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 705-717.	2.9	14
72	Pharmacokinetic interaction involving fenofibrate and everolimus. <i>Annals of Oncology</i> , 2015, 26, 248-249.	0.6	14

#	ARTICLE	IF	CITATIONS
73	Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation. <i>Blood</i> , 2015, 126, 3833-3833.	0.6	1
74	Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma. <i>Blood</i> , 2015, 126, 3835-3835.	0.6	3
75	The Lack of Antitumor Effects of o,pâ€²DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment. <i>Hormones and Cancer</i> , 2014, 5, 312-323.	4.9	19
76	Vemurafenib in pediatric patients with <scp><i>BRAFV</i></scp><i>600E</i> mutated highâ€grade gliomas. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1101-1103.	0.8	125
77	Efficacy and safety of gefitinib during pregnancy: Case report and literature review. <i>Lung Cancer</i> , 2014, 85, 481-484.	0.9	29
78	Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices. <i>Drugs in R and D</i> , 2014, 14, 13-23.	1.1	4
79	Review of therapeutic drug monitoring of anticancer drugs part two â€ Targeted therapies. <i>European Journal of Cancer</i> , 2014, 50, 2020-2036.	1.3	248
80	Therapeutic drug monitoring in cancer â€ Are we missing a trick?. <i>European Journal of Cancer</i> , 2014, 50, 2005-2009.	1.3	79
81	Review of therapeutic drug monitoring of anticancer drugs part 1 â€ Cytotoxics. <i>European Journal of Cancer</i> , 2014, 50, 2010-2019.	1.3	205
82	Pharmacokinetics/Pharmacodynamic Relationship in Busulfan Conditioning Regimen: Results from a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation. <i>Blood</i> , 2014, 124, 425-425.	0.6	1
83	Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2013, 38, 149-157.	0.6	10
84	Physico-Chemical Stability of Busulfan in Injectable Solutions in Various Administration Packages. <i>Drugs in R and D</i> , 2013, 13, 87-94.	1.1	15
85	Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 333-347.	1.5	55
86	First case report of intrathecal panitumumab for treatment of meningeal carcinomatosis in an EGFR mutant lung adenocarcinoma patient. <i>Lung Cancer</i> , 2013, 80, 113-114.	0.9	4
87	Body Composition Variation and Impact of Low Skeletal Muscle Mass in Patients With Advanced Medullary Thyroid Carcinoma Treated With Vandetanib: Results From a Placebo-Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2401-2408.	1.8	88
88	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients. <i>Oncolmmunology</i> , 2013, 2, e23079.	2.1	18
89	Phase I clinical trial combining imatinib mesylate and IL-2. <i>Oncolmmunology</i> , 2013, 2, e23080.	2.1	29
90	Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 371-381.	1.6	75

#	ARTICLE	IF	CITATIONS
91	Population Pharmacokinetics of Busulfan in Children Letter: Figure 1.. Clinical Cancer Research, 2012, 18, 2715-2716.	3.2	4
92	Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older Children. Therapeutic Drug Monitoring, 2012, 34, 198-208.	1.0	76
93	High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. European Journal of Endocrinology, 2012, 166, 261-268.	1.9	50
94	Performance of alfentanil target-controlled infusion in normal and morbidly obese female patients. British Journal of Anaesthesia, 2012, 109, 551-560.	1.5	12
95	Hyperthermic Pelvic Perfusion With Tumor Necrosis Factor- $\alpha$ for Locally Advanced Cancers. Annals of Surgery, 2012, 255, 281-286.	2.1	23
96	Safety and quality assurance of chemotherapeutic preparations in a hospital production unit: Acceptance sampling plan and economic impact. Journal of Oncology Pharmacy Practice, 2012, 18, 163-170.	0.5	7
97	Off-patent Oral Oncology Drugs for Kids (O3K FP7-project): From bedside to PUMA. International Journal of Pharmaceutics, 2012, 435, 148-150.	2.6	1
98	Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma A report from the Soci�t� Fran�saise des Cancers et leuc�mies de l'Enfant et de l'adolescent (SFCE). European Journal of Cancer, 2012, 48, 2409-2416.	1.3	57
99	Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. European Journal of Cancer, 2012, 48, 3063-3072.	1.3	54
100	Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model. American Journal of Obstetrics and Gynecology, 2012, 207, 514.e1-514.e7.	0.7	31
101	Irinotecan Loaded in Eluting Beads: Preclinical Assessment in a Rabbit VX2 Liver Tumor Model. CardioVascular and Interventional Radiology, 2012, 35, 1448-1459.	0.9	36
102	Natural history, management and pharmacokinetics of Everolimus-induced-oral ulcers: Insights into compliance issues. European Journal of Cancer, 2011, 47, 2249-2255.	1.3	42
103	A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary. International Journal of Pharmaceutics, 2011, 414, 285-297.	2.6	16
104	Quantification of dimethyl-ifosfamide and its N-deschloropropylated metabolites in mouse plasma by liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 743-750.	1.2	4
105	Microbiological and Physicochemical Stability of Oxycodone Hydrochloride Solutions for Patient-Controlled Delivery Systems. Journal of Pain and Symptom Management, 2010, 40, 87-94.	0.6	6
106	Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine-Related Cancer, 2010, 17, 797-807.	1.6	52
107	Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. European Journal of Cancer, 2010, 46, 2763-2770.	1.3	20
108	Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 919-938.	1.5	65



#	ARTICLE	IF	CITATIONS
109	Screening for Potential Covariates Influencing the Pharmacokinetics of Intravenous Busulfan: Results From a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation. <i>Blood</i> , 2010, 116, 1811-1811.	0.6	0
110	New Ifosfamide Analogs Designed for Lower Associated Neurotoxicity and Nephrotoxicity with Modified Alkylating Kinetics Leading to Enhanced in Vitro Anticancer Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 328, 598-609.	1.3	14
111	Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry. <i>International Journal of Pharmaceutics</i> , 2009, 379, 235-243.	2.6	16
112	Acoustic characterization of a new trisacryl contrast agent. Part II: Flow phantom study and in vivo quantification. <i>Ultrasonics</i> , 2008, 48, 26-34.	2.1	2
113	Acoustic characterization of a new trisacryl contrast agent. Part I: In vitro study. <i>Ultrasonics</i> , 2008, 48, 16-25.	2.1	8
114	Squalenylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1570-1577.	1.7	86
115	Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists. <i>Journal of Microencapsulation</i> , 2007, 24, 715-730.	1.2	7
116	Induction of Glutathione Synthesis Explains Pharmacodynamics of High-Dose Busulfan in Mice and Highlights Putative Mechanisms of Drug Interaction. <i>Drug Metabolism and Disposition</i> , 2007, 35, 306-314.	1.7	17
117	Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 2237-2240.	1.0	33
118	Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route. <i>International Journal of Pharmaceutics</i> , 2007, 344, 62-70.	2.6	26
119	Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 858, 71-78.	1.2	26
120	Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High-dose Chemotherapy Regimens in Children with Malignant Solid Tumors. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 402-409.	2.3	14
121	Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in an hospital pharmacy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2006, 64, 92-98.	2.0	18
122	Evaluation of the pharmacokinetic profile and analgesic efficacy of oral morphine after total hip arthroplasty. <i>European Journal of Anaesthesiology</i> , 2006, 23, 748-754.	0.7	19
123	Near infrared spectroscopy and process analytical technology to master the process of busulfan paediatric capsules in a university hospital. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2006, 41, 1171-1178.	1.4	31
124	Liquid chromatography-tandem mass spectrometry assay of reduced and oxidized glutathione and main precursors in mice liver. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 832, 67-74.	1.2	58
125	Microbiological and Physicochemical Stability of Fentanyl and Sufentanil Solutions for Patient-Controlled Delivery Systems. <i>Journal of Pain and Symptom Management</i> , 2006, 32, 90-97.	0.6	6
126	Pharmacokinetics, Metabolism, and Routes of Excretion of Intravenous Irofulven in Patients with Advanced Solid Tumors. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1918-1926.	1.7	13



#	ARTICLE	IF	CITATIONS
127	In Vitro Echogenicity Characterization of Poly[lactide-coglycolide] (PLGA) Microparticles and Preliminary In Vivo Ultrasound Enhancement Study for Ultrasound Contrast Agent Application. <i>Investigative Radiology</i> , 2005, 40, 536-544.	3.5	15
128	Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 38, 180-185.	1.4	15
129	Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: Application to camptothecin derivatives. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 39, 581-586.	1.4	30
130	Liquid chromatography-mass spectrometry assay for quantitation of ifosfamide and its -deschloroethylated metabolites in rat microsomal medium. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 820, 251-259.	1.2	12
131	E.F.P. - European Fellowship for Pharmacists Promoting Clinical Pharmacy in Europe. <i>International Journal of Clinical Pharmacy</i> , 2005, 27, 278-278.	1.4	0
132	Microbial growth tests in anti-neoplastic injectable solutions. <i>Journal of Oncology Pharmacy Practice</i> , 2005, 11, 7-12.	0.5	6
133	High-performance thin-layer chromatography with a derivatization procedure, a suitable method for the identification and the quantitation of busulfan in various pharmaceutical products. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 34, 525-530.	1.4	17
134	Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. <i>Medical Science Monitor</i> , 2004, 10, CR209-12.	0.5	33
135	Identification and quantitation of antineoplastic compounds in chemotherapeutic infusion bags by use of HPTLC: application to the vinca-alkaloids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 30, 1603-1610.	1.4	34
136	Contribution of high-performance thin-layer chromatography to a pharmaceutical quality assurance programme in a hospital chemotherapy manufacturing unit. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2003, 56, 445-451.	2.0	19
137	Human Pharmacokinetic Study of Heated Intraperitoneal Oxaliplatin in Increasingly Hypotonic Solutions after Complete Resection of Peritoneal Carcinomatosis. <i>Oncology</i> , 2002, 63, 346-352.	0.9	89
138	Dual-mode gradient HPLC procedure for the simultaneous determination of chloroquine and proguanil. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 27, 1-7.	1.4	21
139	Separation methods for alkylating antineoplastic compounds. <i>Biomedical Applications</i> , 2001, 764, 255-287.	1.7	15
140	Anodic Oxidation of Ifosfamide and Cyclophosphamide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 1347-1349.	1.0	34
141	Synthesis of side-chain-substituted ifosfamide analogs. <i>Journal of Heterocyclic Chemistry</i> , 2001, 38, 1131-1134.	1.4	6
142	Quantitative high-performance liquid chromatographic determination of acrolein in plasma after derivatization with Luminarin® 3. <i>Biomedical Applications</i> , 2000, 739, 239-246.	1.7	19